Immunome Inc’s recent filing unveils that its Director BIENAIME JEAN JACQUES acquired Company’s shares for reported $46900.0 on Jun 03 ’25. In the deal valued at $9.38 per share,5,000 shares were bought. As a result of this transaction, BIENAIME JEAN JACQUES now holds 36,415 shares worth roughly $0.51 million.
Then, BIENAIME JEAN JACQUES bought 7,800 shares, generating $60,684 in total proceeds. Upon buying the shares at $7.78, the Director now owns 31,415 shares.
Before that, SIEGALL CLAY B bought 137,100 shares. Immunome Inc shares valued at $999,459 were divested by the President and CEO at a price of $7.29 per share. As a result of the transaction, SIEGALL CLAY B now holds 806,736 shares, worth roughly $11.37 million.
Goldman initiated its Immunome Inc [IMNM] rating to a Buy in a research note published on September 22, 2025; the price target was $26. A number of analysts have revised their coverage, including Craig Hallum’s analysts, who began to cover the stock in early September with a ‘”a Buy”‘ rating. Lake Street began covering IMNM with “Buy” recommendation on April 02, 2025. Stephens started covering the stock on November 08, 2024. It rated IMNM as “an Overweight”.
Price Performance Review of IMNM
On Tuesday, Immunome Inc [NASDAQ:IMNM] saw its stock fall -1.05% to $14.1. Over the last five days, the stock has gained 2.03%. Immunome Inc shares have risen nearly 18.79% since the year began. Nevertheless, the stocks have risen 32.77% over the past one year.
How much short interest is there in Immunome Inc?
A steep rise in short interest was recorded in Immunome Inc stocks on 2025-09-30, growing by 1.9 million shares to a total of 15.47 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-29 was 13.56 million shares. There was a rise of 12.31%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on May 31, 2024 when Piper Sandler began covering the stock and recommended ‘”an Overweight”‘ rating along with a $27 price target.
